A decade ago Agensys’ antibody work looked so appealing that Astellas happily paid $387 million in cash for it, reserving $150 million more in milestones. Today, though, the Japanese pharma company says it is shutting down the operation in Santa Monica, CA and moving on from antibody-drug conjugations, laying off all of the 220 staffers … Continue reading Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech